CYTK 250117 85.00P (CYTK250117P85000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

CYTK250117P85000

Watchlist

17.91
0.000.00%

15min DelayTrading Feb 23 13:18 ET

0.00High0.00Low

Intraday

5D
Daily

News

Cytokinetics Says European Regulator Validated Its Application for Cardiomyopathy Drug Candidate
MT NewswiresDec 23 08:03 ET
Cytokinetics Announces EMA Has Validated MAA for Aficamten
TipRanksDec 23 07:40 ET
Truist Financial Maintains Cytokinetics(CYTK.US) With Buy Rating
Moomoo NewsDec 23 07:31 ET · Ratings
Express News | Cytokinetics Inc - FDA Sets Pdufa Target Action Date for Aficamten Nda as Sept 26, 2025
ReutersDec 23 07:30 ET
Express News | Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
ReutersDec 23 07:30 ET
Truist Financial Sticks to Their Buy Rating for Cytokinetics (CYTK)
TipRanksDec 23 07:15 ET · Ratings

Comments

Sean Parker

Nov 19 02:56

$Cytokinetics (CYTK.US)$
Cytokinetics (CYTK) and Bayer have established an exclusive licensing agreement for aficamten in Japan, focusing on treating hypertrophic cardiomyopathy (HCM). The deal includes an upfront payment of €50 million to Cytokinetics, with potential additional earnings of €90 million in milestones through commercial launch (including €20 million near-term) and up to €490 million in commercial milestone payments. The collaboration involves tiered royalties on Japanese sales and ...

Mr Long Term

Aug 13 17:42

Columns Top Calls on Wall Street: Starbucks, Dell, Warner Bros. and More.

Top 5 Upgrades:
Baird upgraded Starbucks $Starbucks (SBUX.US)$ to Outperform from Neutral with a price target of $110, up from $81. The firm sees a more favorable risk/reward on Starbucks shares following the hiring of Brian Niccol as CEO.
Barclays upgraded Dell Technologies $Dell Technologies (DELL.US)$ to Equal Weight from Underweight with an unchanged price target of $97. The firm says much of the artificial intelligence "hype" ...

Rocketier (MAXN)

Jun 11 07:25

$Cytokinetics (CYTK.US)$ cmonnn I know u can up alot further! 🚀

Rocketier (MAXN)

May 29 13:05

$Cytokinetics (CYTK.US)$ will there be potential to gain back 100 after the offering?

zulia3003

May 23 09:02

$Cytokinetics (CYTK.US)$ why drop